PCR was performed with Q5 DNA polymerase (New England Biolabs, Ipswich, MA)
In addition, effective June 1, 2026, Caremark will lift the new-to-market block on Foundayo (orforglipron), an oral GLP-1 therapy, for plans that approve coverage
BPC-157 was removed from the FDAs Category 2 restricted list on April 23, 2026
Vitamin C offers impressive benefits as well
Metabolic coupling and the Reverse Warburg Effect in cancer: Implications for novel biomarker and anticancer agent development
There are some clear biases possible when a company funds a study, the researchers may feel pressured to produce certain results, or the company can repeat a study until it gets favorable results but some information is better than none